Основная статистика
| CIK | 1685428 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LumiraDx Limited
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| November 12, 2024 |
LMDXF / LumiraDx Limited / Senvest Management, LLC - LUMIRADX LIMITED Passive Investment SC 13G/A 1 p24-2922sc13ga.htm LUMIRADX LIMITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| October 4, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024. Commission File Number: 001-40852 LUMIRADX LIMITED (In Official Liquidation) (Translation of registrant’s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limite |
|
| February 12, 2024 |
LMDX / LumiraDx Limited / PETRICHOR HEALTHCARE CAPITAL MANAGEMENT LP - SC 13G/A Passive Investment SC 13G/A 1 d760465dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LUMIRADX LIMITED (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check |
|
| February 9, 2024 |
LMDX / LumiraDx Limited / Senvest Management, LLC - LUMIRADX LIMITED Passive Investment SC 13G/A 1 p24-0326sc13ga.htm LUMIRADX LIMITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024. Commission File Number: 001-40852 LUMIRADX LIMITED (In Official Liquidation) (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited P |
|
| December 29, 2023 |
LMDX / LumiraDx Limited / UMPHREY WILLARD L - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Willard L. Umphrey 76 Red Coat Lane Concord, MA 01742 (781) 676-5906 (Name, Address and Telephone Number of Person Aut |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| December 26, 2023 |
LMDX / LumiraDx Limited / UMPHREY WILLARD L - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Willard L. Umphrey 76 Red Coat Lane Concord, MA 01742 (781) 676-5906 (Name, Address and Telephone Number of Person Aut |
|
| December 20, 2023 |
LMDX / LumiraDx Limited / UMPHREY WILLARD L - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Willard L. Umphrey 76 Red Coat Lane Concord, MA 01742 (781) 676-5906 (Name, Address and Telephone Number of Person Au |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| November 21, 2023 |
Exhibit 4.1 SIXTEENTH AMENDMENT This SIXTEENTH AMENDMENT (this “Sixteenth Amendment”) is entered into as of November 20, 2023 (the “Sixteenth Amendment Effective Date”), by and among LumiraDx Investment Limited, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (the “Borrower”), LumiraDx Group Limited, a private company with limi |
|
| November 8, 2023 |
LMDX / LumiraDx Limited / MCALEER JEROME F - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Jerome F. McAleer 52 Nobles Close Grove, OX12 0NR United Kingdom +44 199 377 6060 (Name, Address and Telepho |
|
| November 8, 2023 |
LMDX / LumiraDx Limited / SCOTT DAVID - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) David Scott Units SCF 1&2 Western International Market Hayes Road, Southall, UB2 5XJ United Kingdom +44 208 |
|
| November 7, 2023 |
LMDX / LumiraDx Limited / Zwanziger Ventures LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Zwanziger Ventures LLC PO Box 156 Waban, MA, 02468 (Name, Address and Telephone Number of Person Authorized t |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| October 31, 2023 |
Exhibit 4.1 FIFTEENTH AMENDMENT This FIFTEENTH AMENDMENT (this “Fifteenth Amendment”) is entered into as of October 31, 2023 (the “Fifteenth Amendment Effective Date”), by and among LumiraDx Investment Limited, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (the “Borrower”), LumiraDx Group Limited, a private company with limit |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| October 27, 2023 |
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal Exhibit 99.1 LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal LONDON, October 27, 2023 (GLOBE NEWSWIRE) – On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company th |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| October 3, 2023 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations Unless the context otherwise requires, references to “LumiraDx,” “we,” “us,” “our,” or the “Company” refer to LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and its consolidated subsidiaries. The following discussion and analysis of our |
|
| October 3, 2023 |
Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Financial Statements of LumiraDx Limited Unaudited Consolidated Statement of Profit and Loss and Comprehensive Loss for the periods ended June 30, 2023 and 2022. F-1 Unaudited Consolidated Statement of Financial Position as of June 30, 2023 and December 31, 2022. F-2 Unaudited Consolidated Statement of Changes |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, R |
|
| September 26, 2023 |
Exhibit 4.1 TWELFTH AMENDMENT AND WAIVER This TWELFTH AMENDMENT AND WAIVER (this “Twelfth Amendment”) is entered into as of September 25, 2023 (the “Twelfth Amendment Effective Date”), by and among LumiraDx Investment Limited, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (the “Borrower”), LumiraDx Group Limited, a private co |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, R |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Rega |
|
| August 24, 2023 |
LumiraDx Reports Second Quarter 2023 Results Exhibit 99.1 LumiraDx Reports Second Quarter 2023 Results LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) - LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. • Second quarter 2023 revenues of $21.0 million • Submitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Rega |
|
| July 21, 2023 |
Exhibit 4.1 NINTH AMENDMENT AND WAIVER This NINTH AMENDMENT AND WAIVER (this “Ninth Amendment”) is entered into as of July 20, 2023 (the “Ninth Amendment Effective Date”), by and among LumiraDx Investment Limited, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (the “Borrower”), LumiraDx Group Limited, a private company with li |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatt |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatt |
|
| July 17, 2023 |
EIGHTH AMENDMENT TO LOAN AGREEMENT Exhibit 4.1 EIGHTH AMENDMENT TO LOAN AGREEMENT This EIGHTH AMENDMENT TO LOAN AGREEMENT (this “Eighth Amendment”), dated and effective as of July 17, 2023 (the “Eighth Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatt |
|
| June 30, 2023 |
SEVENTH AMENDMENT TO LOAN AGREEMENT Exhibit 4.1 SEVENTH AMENDMENT TO LOAN AGREEMENT This SEVENTH AMENDMENT TO LOAN AGREEMENT (this “Seventh Amendment”), dated and effective as of June 30, 2023 (the “Seventh Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Part |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant’s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatt |
|
| June 7, 2023 |
SIXTH AMENDMENT TO LOAN AGREEMENT Exhibit 4.1 SIXTH AMENDMENT TO LOAN AGREEMENT This SIXTH AMENDMENT TO LOAN AGREEMENT (this “Sixth Amendment”), dated and effective as of June 7, 2023 (the “Sixth Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), BIOPH |
|
| May 16, 2023 |
LumiraDx Reports First Quarter 2023 Results Exhibit 99.1 LumiraDx Reports First Quarter 2023 Results LONDON, May 16, 2023 (GLOBE NEWSWIRE) - LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. • First quarter 2023 revenues of $22.2 million. • Cost reduction programs implemented across the global organization resulting in dec |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta |
|
| May 11, 2023 |
Acceleration Request VIA EDGAR May 11, 2023 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 F-3 Table of Contents As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Registered Securities Fees to Be Paid Equity Common Shares, par value $0. |
|
| May 1, 2023 |
Exhibit 4.25 dwf MINUTE OF EXTENSION, VARIATION AND GRANT OF LEASE between THE TRUSTEES FOR THE ASHTENNE INDUSTRIAL FUND LIMITED PARTNERSHIP and LUMIRADX UK LIMITED Subjects: Unit 3A Dumyat Business Park, Alloa DWF LLP No. 2 Lochrin Square 96 Fountainbridge Edinburgh EH3 9QA 81719655-2 CONTENTS 1. Definitions 1 2. Extension and Variation of Lease Terms 2 3. Terms of Lease 2 4. Costs 2 5. Counterpa |
|
| May 1, 2023 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED LumiraDx Limited (“LumiraDx”) has two classes of securities registered under Section 12 of the Securities Exchange Act, as amended (the “Exchange Act”): common shares and warrants to purchase common shares. The following summary of the general terms and provis |
|
| May 1, 2023 |
Consent of KPMG LLP, independent public registered accounting firm for LumiraDx Limited. Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements on Form S-8 (File No: 333-259874 and File No. 333-264611), and on Form F-3 (File No: 333-264609) of our report dated May 1, 2023, with respect to the consolidated financial statements of LumiraDx Limited. /s/ KPMG LLP London, United Kingdom May 1, 2023 |
|
| May 1, 2023 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report on Form 20-F of LumiraDx Limited (the “Company”) for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer h |
|
| May 1, 2023 |
Exhibit 4.19 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. GRANT AGREEMENT [***] AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: LumiraDx UK Limited Tax Status: Not exempt fro |
|
| May 1, 2023 |
Exhibit 4.11 Between: (1) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1-1108, Cayman Islands (2) USB Focus Fund LumiraDx 2A, LLC, including as successor by merger to USB Focus Fund LumiraDx 2B, LLC 55 Old Bedford Road, Lincoln, Massachusetts 01773 (3) Pacific Premier Trust Custodian FBO Willard L. Umphrey Roth IRA (4) Pacific Pr |
|
| May 1, 2023 |
Exhibit 4.13 PREFERRED SHARE INVESTOR RIGHTS LETTER To: Bill & Melinda Gates Foundation (the Preferred Investor or you) PO Box 23350 Seattle, WA 98102 USA Attention: Chief Financial Officer Date: 17 July 2018 Dear Preferred Investor, Rights in connection with offer to subscribe for Series A 8% Cumulative Convertible Preferred Shares We refer to the preferred share subscription letter entered into |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 1, 2023 |
Exhibit 4.12 PREFERRED SHARE INVESTOR RIGHTS LETTER To: Morningside Venture Investments Limited (the Preferred Investor or you) 2nd Floor, Le Prince de Galles 3-5 Avenue des Citronniers MC 98000, Monaco Date: 17 July 2018 Dear Preferred Investor, Rights granted in connection with offer to subscribe for Series A 8% Cumulative Convertible Preferred Shares We refer to the preferred share subscription |
|
| May 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, par value $0. |
|
| May 1, 2023 |
Exhibit 4.16 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT 2 to GRANT AGREEMENT [***] AMENDMENT SUMMARY & SIGNATURE PAGE AMENDMENT INFORMATION Agreement to be Amended: Grant agre |
|
| May 1, 2023 |
Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a). Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Ron Zwanziger, certify that: 1. I have reviewed this Annual Report on Form 20-F of LumiraDx Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements |
|
| May 1, 2023 |
Exhibit 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report on Form 20-F of LumiraDx Limited (the “Company”) for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer h |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a). Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Dorian LeBlanc, certify that: 1. I have reviewed this Annual Report on Form 20-F of LumiraDx Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| May 1, 2023 |
Exhibit 2.22 FIFTH AMENDMENT TO LOAN AGREEMENT This FIFTH AMENDMENT TO LOAN AGREEMENT (this “Fifth Amendment”), dated and effective as of March 1, 2023 (the “Fifth Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), BIO |
|
| April 24, 2023 |
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency LONDON, April 24, 2023 (GLOBE NEWSWIRE) - LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for continued l |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| April 6, 2023 |
LumiraDx Announces Strategic Refocus and Cost Restructuring Program Exhibit 99.1 LumiraDx Announces Strategic Refocus and Cost Restructuring Program LONDON, April 6, 2023 (GLOBE NEWSWIRE) – LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further evolve LumiraDx into |
|
| March 21, 2023 |
LumiraDx Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 LumiraDx Reports Fourth Quarter and Full Year 2022 Results LONDON, March 21, 2023 – LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022. • Full year 2022 revenues of $254.5 million. • Q4 2022 revenue of $41.1 million compared to Q3 2022 revenue of $42. |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| March 7, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant’s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, R |
|
| March 7, 2023 |
March 2023 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. EX-99.1 Exhibit 99.1 March 2023 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Disclaimer FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” |
|
| February 23, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Dated: February 23, 2023 For and on |
|
| February 23, 2023 |
LMDX / LumiraDx Limited / Morningside Venture Investments Ltd - SC 13D/A Activist Investment SC 13D/A CUSIP No. G5709L 109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L 109 (CUSIP Number) Morningside Venture Investments Limited C/O THC Management Services S.A.M., 2nd Floor, |
|
| February 22, 2023 |
EX-4 2 lmdx-ex41.htm EX-4.1 Exhibit 4.1 FOURTH AMENDMENT AND WAIVER This FOURTH AMENDMENT AND WAIVER (this “Amendment and Waiver”), dated and effective as of February 22, 2023 (the “Fourth Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| February 17, 2023 |
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements LONDON, February 17, 2023 (GLOBE NEWSWIRE) - LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). On January 27, 2023, |
|
| February 14, 2023 |
EX-99.1 2 d405390dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Dated: F |
|
| February 14, 2023 |
LMDX / LumiraDx Ltd / Morningside Venture Investments Ltd - SC 13D Activist Investment SC 13D 1 d405390dsc13d.htm SC 13D CUSIP No. G5709L 109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L 109 (CUSIP Number) Morningside Venture Investments Limited C/O THC Management Serv |
|
| February 13, 2023 |
LMDX / LumiraDx Ltd / PETRICHOR HEALTHCARE CAPITAL MANAGEMENT LP - SC 13G/A Passive Investment SC 13G/A 1 d433086dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LUMIRADX LIMITED (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check |
|
| February 10, 2023 |
LMDX / LumiraDx Ltd / Senvest Management, LLC - LUMIRADX LTD Passive Investment SC 13G/A 1 p23-0723sc13ga.htm LUMIRADX LTD SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| January 31, 2023 |
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency Exhibit 99.1 LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) - LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)( |
|
| December 19, 2022 |
Exhibit 99.1 LumiraDx latest cost reduction program continues progress toward operating cash flow breakeven by the end of 2023 December 19, 2022 (London): LumiraDx Limited (Nasdaq: LMDX) today announced further cost reductions across all global functions to adjust to current market conditions and focus on high value assay launches on its transformational point of care platform. The most recent red |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| November 15, 2022 |
Exhibit 99.1 LUMIRADX LIMITED c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108, Cayman Islands (354) 640-0540 NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 15, 2022 Dear Shareholder, You are cordially invited to attend the 2022 Annual General Meeting of Shareholders of LumiraDx Limited (?LumiraDx? or the ?Company?), which will be held |
|
| November 15, 2022 |
Exhibit 99.2 LUMIRADX LIMITED C/O OCORIAN TRUST (CAYMAN) LIMITED PO BOX 1350, WINDWARD 3, REGATTA OFFICE PARK GRAND CAYMAN KY1-1108, CAYMAN ISLANDS VOTE BY INTERNET Before The Meeting?Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m. Eastern Time on December 14, 2022 for shares h |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| November 9, 2022 |
EXHIBIT 99.1 LumiraDx Reports Third Quarter 2022 Results Progress on Near-Term Growth Opportunities and Cost Savings LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) - LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the third quarter ended September 30, 2022. Q3 2022 revenue of $42.2 million compared to Q2 2022 |
|
| November 9, 2022 |
6-K 1 f6k110922.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-40852 LumiraDx Limited (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limite |
|
| October 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table Post-effective Amendment No. 1 to Form F-1 on Form F-3 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant?s Name into English) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed |
|
| October 4, 2022 |
As filed with the Securities and Exchange Commission on October 4, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 4, 2022 Registration No. |
|
| September 29, 2022 |
Exhibit 99.1 September 2022 Disclaimer FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as ?believe,? ?may,? ?will,? ?estimate,? ?continue,? ?anticipate,? ?intend,? ?expect,? ?should,? ?would,? ?plan,? ?project,? ?forecast |
|
| September 29, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264609 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated June 6, 2022) LumiraDx Limited 43,264,149 Common Shares, $29,500,000 6.00% Convertible Senior Subordinated Notes due 2027, and 4,442,835 Common Shares Issuable Upon Conversion of 6.00% Convertible Senior Subordinated Notes due 2027 This prospectus supplement supplements the prospectus date |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Re |
|
| September 28, 2022 |
Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Page Unaudited Interim Consolidated Financial Statements of LumiraDx Limited Unaudited Consolidated Statement of Profit and Loss and Comprehensive Loss for the periods ended June 30, 2022 and 2021 F-1 Unaudited Consolidated Statement of Financial Position as of June 30, 2022 and December 31, 2021 F-2 Unaudited Consolidated Statement of Changes in Equity f |
|
| September 28, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Unless the context otherwise requires, references to ?LumiraDx,? ?we,? ?us,? ?our,? or the ?Company? refer to LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and its consolidated subsidiaries. The following discussion and analysis of our |
|
| September 7, 2022 |
LMDX / LumiraDx Ltd / UMPHREY WILLARD L - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Willard L. Umphrey 76 Red Coat Lane Concord, MA 01742 (781) 676-5906 (Name, Address and Telephone Number of Pers |
|
| September 7, 2022 |
EX-99.A Exhibit A JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each sha |
|
| September 6, 2022 |
LMDX / LumiraDx Ltd / SCOTT DAVID - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) David Scott LumiraDx, Inc. 221 Crescent Street, 5th Floor Waltham, MA 02543 (888) 586-4721 (Name, Address and Telephone |
|
| August 24, 2022 |
LMDX / LumiraDx Ltd / MCALEER JEROME F - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Jerome F. McAleer LumiraDx, Inc. 221 Crescent Street, 5th Floor Waltham, MA 02543 (888) 586-4721 (Name, Address and Telephone Number of P |
|
| August 18, 2022 |
EXHIBIT 99.1 LumiraDx Reports Second Quarter 2022 Results Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) - LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second quarter ended June 30, 2022. Q2 2022 revenue of $44.7 mi |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022. Commission File Number: 001-40852 LumiraDx Limited (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| August 16, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264609 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated June 6, 2022) LumiraDx Limited 43,264,149 Common Shares, $29,500,000 6.00% Convertible Senior Subordinated Notes due 2027, and 4,442,835 Common Shares Issuable Upon Conversion of 6.00% Convertible Senior Subordinated Notes due 2027 This prospectus supplement supplements t |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Reg |
|
| August 3, 2022 |
LMDX / LumiraDx Ltd / Bill & Melinda Gates Foundation Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Lumira Dx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Connie Collingsworth, Esq. 500 Fifth Avenue North Seattle, WA 98109 (206) 709-3100 (Name, Address and Telephone Number |
|
| July 29, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264609 PROSPECTUS SUPPLEMENT (to Prospectus dated June 6, 2022) LumiraDx Limited 43,264,149 Common Shares, $29,500,000 6.00% Convertible Senior Subordinated Notes due 2027, and 4,442,835 Common Shares Issuable Upon Conversion of 6.00% Convertible Senior Subordinated Notes due 2027 This prospectus supplement supplements the prospectus dated June |
|
| July 28, 2022 |
LMDX / LumiraDx Ltd / Zwanziger Ventures LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Zwanziger Ventures LLC 148 Dartmouth Street Newton, MA 02465 (Name, Address and Telephone Number of Person Authorized t |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| July 21, 2022 |
43,000,000 Shares Common Shares Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-266207 43,000,000 Shares Common Shares We are offering 43,000,000 of our common shares, par value $0.0000028 per common share (?common shares?). Our common shares are listed on the Nasdaq Global Market under the symbol ?LMDX?. On July 20, 2022, the last reported sale price of our common shares as reported on Nasdaq Global Mark |
|
| July 19, 2022 |
Exhibit 4.19 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) are the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this ?Agreement?) is made and entered into as of July 19, 2022 |
|
| July 19, 2022 |
EX-10.25 7 d336249dex1025.htm EX-10.25 Exhibit 10.25 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) are the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. ROYALTY AGREEMENT between LUMIRADX LIMITED and USB FOCUS FUND LUMIRADX 2A, |
|
| July 19, 2022 |
July 19, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 19, 2022 |
CORRESP 1 filename1.htm July 19, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Abby Adams Re: LumiraDx Limited Registration Statement on Form F-1 File No. 333-266207 Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities A |
|
| July 19, 2022 |
Exhibit 4.14 THIRD AMENDMENT TO LOAN AGREEMENT This THIRD AMENDMENT TO LOAN AGREEMENT (this ?Third Amendment?), dated and effective as of July 18, 2022 (the ?Third Amendment Effective Date?), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as ?Borrower? and a Credit Party), BIO |
|
| July 19, 2022 |
EX-4.12 3 d336249dex412.htm EX-4.12 Exhibit 4.12 FIRST AMENDMENT TO LOAN AGREEMENT This FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of March 28, 2022 (the “Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Cre |
|
| July 19, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Registered Securities Fees to Be Paid Equity Common Shares, par value $0. |
|
| July 19, 2022 |
Exhibit 1.1 LUMIRADX LIMITED Common Shares, par value $0.0000028 per common share Underwriting Agreement [?], 2022 Goldman Sachs & Co. LLC Evercore Group L.L.C. SVB Securities LLC Raymond James & Associates, Inc. As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Evercore Group |
|
| July 19, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on July 1 9 , 2022. |
|
| July 15, 2022 |
LMDX / LumiraDx Ltd / Bill & Melinda Gates Foundation Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) N/A (Date of Event Which Requires Filing of this Statement) (Note: This Schedule 13G is being filed voluntarily as it i |
|
| July 15, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT We, the signatories of the statement to which this Joint Filing Agreement is attached, hereby agree that such statement is filed, and any amendments thereto filed by any or all of us, will be filed, on behalf of each of us. Date: July 14, 2022 BILL & MELINDA GATES FOUNDATION By: /s/ Connie Collingsworth Name: Connie Collingsworth Title: Chief Operating Officer a |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regat |
|
| June 21, 2022 |
Exhibit 4.2 DATED: 17 JUNE 2022 LUMIRADX LIMITED AND BIOPHARMA CREDIT PLC AND BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP DEED OF AMENDMENT of a Warrant Instrument dated 28 September 2021 THIS DEED OF AMENDMENT (?DEED?) is executed on 17 June 2022 by LumiraDx Limited (company number 314391), a company incorporated in the Cayman Islands, whose registered office is at Ocorian Trust (Cayman) Limited, |
|
| June 21, 2022 |
Ilumiradxtm Transforming community-based healthcare June 21, 2022 Exhibit 99.1 Ilumiradxtm Transforming community-based healthcare June 21, 2022 Introduction To The Speakers Ron Zwanziger CEO, Co-Founder, Chairman and Director Veronique Ameye Executive Vice President Dorian LeBlanc CFO and Vice President,Global Operations Pooja Pathak Chief Product Officer Matthew Fay Medical Director Jeanne Mumford PathologyManager Johns Hopkins Hospital Pete Grisafi President |
|
| June 21, 2022 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 21, 2022. |
|
| June 21, 2022 |
Exhibit 4.1 SECOND AMENDMENT TO LOAN AGREEMENT This SECOND AMENDMENT TO LOAN AGREEMENT (this ?Second Amendment?), dated and effective as of June 17, 2022 (the ?Amendment Effective Date?), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as ?Borrower? and a Credit Party), BIOPHAR |
|
| June 7, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264609 PROSPECTUS LumiraDx Limited 43,264,149 Common Shares, $29,500,000 6.00% Convertible Senior Subordinated Notes due 2027, and 4,442,835 Common Shares Issuable Upon Conversion of 6.00% Convertible Senior Subordinated Notes due 2027 This prospectus relates to the offer and sale from time to time by the selling securityholde |
|
| June 2, 2022 |
VIA EDGAR June 2, 2022 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| May 27, 2022 |
Goodwin Procter LLP The New York Times Building 620 Eighth Avenue New York, New York 10018 goodwinlaw. |
|
| May 27, 2022 |
As filed with the Securities and Exchange Commission on May 27, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 27, 2022 Registration No. |
|
| May 27, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant?s Name into English) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common shares, par value $0. |
|
| May 13, 2022 |
Transforming Community-Based Healthcare May 2022 Exhibit 99.1 FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as ?believe,? ?may,? ?will,? ?estimate,? ?continue,? ?anticipate,? ?intend,? ?expect,? ?should,? ?would,? ?plan |
|
| May 13, 2022 |
6-K 1 d265461d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant’s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box |
|
| May 11, 2022 |
Exhibit 99.1 LumiraDx Reports First Quarter 2022 Results Strong Growth in Instruments Delivered to Customers and Continued Innovation on our Platform London, UK (May 11, 2022), LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the first quarter ended March 31, 2022. ? For the first three months of 2022, |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatt |
|
| May 2, 2022 |
Power of Attorney (included on signature page to the June 2022 Registration Statement). Table of Contents As filed with the Securities and Exchange Commission on May 2, 2022 Registration No. |
|
| May 2, 2022 |
As filed with the Securities and Exchange Commission on May 2, 2022 As filed with the Securities and Exchange Commission on May 2, 2022 Registration No. |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, par value $0. |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) LumiraDx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Debt 6. |
|
| May 2, 2022 |
Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| April 28, 2022 |
6-K 1 royaltydeal.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022. Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant's name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO |
|
| April 13, 2022 |
Consent of KPMG LLP, independent public registered accounting firm for LumiraDx Limited. EX-15.1 11 lmdx-ex151.htm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333- 259874) on Form S-8 of our report dated April 13, 2022, with respect to the consolidated financial statements of LumiraDx Limited. /s/ KPMG LLP London, United Kingdom April 13, 2022 |
|
| April 13, 2022 |
Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a). Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Dorian LeBlanc, certify that: 1. I have reviewed this Annual Report on Form 20-F of LumiraDx Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| April 13, 2022 |
Exhibit 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report on Form 20-F of LumiraDx Limited (the “Company”) for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer h |
|
| April 13, 2022 |
Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a). Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Ron Zwanziger, certify that: 1. I have reviewed this Annual Report on Form 20-F of LumiraDx Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements |
|
| April 13, 2022 |
Exhibit 4.18 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. FIRST AMENDMENT TO PURCHASE AGREEMENT BETWEEN CVS PHARMACY, INC. AND LUMIRADX, INC. THIS FIRST AMENDMENT TO THE PURCHASE AGREEMEN |
|
| April 13, 2022 |
Exhibit 4.31 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. LEASE BY AND BETWEEN DRAWBRIDGE NANCY RIDGE, LLC, a Delaware limited liability company as Landlord and LUMIRADX, INC., a Delaware |
|
| April 13, 2022 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report on Form 20-F of LumiraDx Limited (the “Company”) for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer h |
|
| April 13, 2022 |
Exhibit 4.30 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. LEASE between BNP PARIBAS DEPOSITARY SERVICES (JERSEY) LIMITED AND BNP PARIBAS DEPOSITARY SERVICES LIMITED AS TRUSTEES OF THE MAY |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 13, 2022 |
EX-2.12 2 lmdx-ex212.htm EX-2.12 Exhibit 2.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED LumiraDx Limited (“LumiraDx”) has two classes of securities registered under Section 12 of the Securities Exchange Act, as amended (the “Exchange Act”): common shares and warrants to purchase common shares. The following summa |
|
| March 10, 2022 |
EX-99.1 Exhibit 99.1 LumiraDx Reports Fourth Quarter and Full Year 2021 Results Positive Customer Experience Drives Market Adoption and Expands Use Cases for LumiraDx’s Transformative Diagnostic Solutions London, UK (March 10, 2022), LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the fourth quarter an |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2022 Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta |
|
| March 9, 2022 |
Transforming Community-Based Healthcare March 2022 Exhibit 99.1 FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as ?believe,? ?may,? ?will,? ?estimate,? ?continue,? ?anticipate,? ?intend,? ?expect,? ?should,? ?would,? ?pl |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-40852 LUMIRADX LIMITED LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Isla |
|
| March 3, 2022 |
Exhibit 4.1 EXECUTION VERSION LUMIRADX LIMITED and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 3, 2022 6.00% Convertible Senior Subordinated Notes due 2027 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 17 Section 1.03. Rules of Construction 18 Article 2. The Notes 18 Sectio |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 3, 2022 Commission File Number: 001-40852 LUMIRADX LIMITED LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands (345) 640-0 |
|
| March 3, 2022 |
Exhibit 4.3 Registration Rights Agreement March 3, 2022 LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands Attn: Dorian LeBlanc, Chief Financial Officer Ladies and Gentlemen: LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the ?Company?), has agreed to |
|
| March 1, 2022 |
EX-10.1 2 d278050dex101.htm EX-10.1 Exhibit 10.1 Subscription Agreement March, 2022 LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands Attn: Dorian LeBlanc, Chief Financial Officer Re: Subscription for 6.00% Convertible Senior Subordinated Notes due 2027 Ladies and Gentlemen: LumiraDx Limited, an exempted company wi |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 1, 2022 Commission File Number: 001-40852 LUMIRADX LIMITED LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands (345) 640-0 |
|
| March 1, 2022 |
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering Exhibit 99.1 LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering March 1, 2022 (London): LumiraDx Limited (Nasdaq: LMDX) announced today that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase from LumiraDx (the ?notes offering?) $56.5 million aggregate principal amoun |
|
| February 24, 2022 |
LMDX / LumiraDx Ltd / Zwanziger Ventures LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Zwanziger Ventures LLC 148 Dartmouth Street Newton, MA 02465 (Name, Address and Telephone Number of Person Authorized to Receive Notices |
|
| February 24, 2022 |
LMDX / LumiraDx Ltd / PETRICHOR HEALTHCARE CAPITAL MANAGEMENT LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LUMIRADX LIMITED (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2022 |
LMDX / LumiraDx Ltd / Morningside Venture Investments Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LUMIRADX LIMITED (Name of Issuer) Common shares, par value $0.0000028 per share (Title of Class of Securities) G5709L 109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 14, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. Dated: Fe |
|
| February 9, 2022 |
LMDX / LumiraDx Ltd / Senvest Management, LLC - LUMIRADX LIMITED Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LumiraDx Limited (Name of Issuer) Common Shares, par value $0.0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) September 28, 2021, December 31, 2021 and January 26, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 18, 2022 Commission File Number: 001-40852 LUMIRADX LIMITED LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands (345) 64 |
|
| January 18, 2022 |
Transforming Community-Based Healthcare January 18, 2022 Exhibit 99.1 FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as ?believe,? ?may,? ?will,? ?estimate,? ?continue,? ?anticipate,? ?intend,? ?expect,? ?should,? ?would |
|
| January 11, 2022 |
6-K 1 d247171d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 11, 2022 Commission File Number: 001-40852 LUMIRADX LIMITED LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-110 |
|
| January 11, 2022 |
Exhibit 99.1 LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test Company Announces Preliminary Revenue for Fourth Quarter and Full Year 2021 London, UK (January 11, 2022): LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue. |
|
| November 22, 2021 |
Transforming Community-Based Healthcare November 2021 Confidential and Proprietary Copyright ? 2021 LumiraDx Ltd. |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 22, 2021 Commission File Number: 001-40852 LUMIRADX LIMITED LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands (345) 6 |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-40852 LUMIRADX LIMITED (Translation of registrant?s name into English) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatt |
|
| November 10, 2021 |
Exhibit 99.1 LumiraDx Reports Third Quarter 2021 Financial Results Strong Revenue Growth and Strategic Progress on Platform, Products and Pipeline London, UK (November 10, 2021), LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. ? Revenue of $109.1M for the three months ended Sept. 30, 2021 |
|
| September 29, 2021 |
Consent of Marcum LLP, independent registered accounting firm for CA Healthcare Acquisition Corp. EX-15.2 8 d192384dex152.htm EX-15.2 Exhibit 15.2 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT We consent to the incorporation by reference in the Shell Company Report Form 20-F pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 of LumiraDx Limited of our report dated January 8, 2021, except for the second paragraph in Note 7 as to which the date is April 20, 2021, wi |
|
| September 29, 2021 |
Exhibit 2.3 AMENDED AND RESTATED WARRANT AGREEMENT THIS AMENDED AND RESTATED WARRANT AGREEMENT (this ?Agreement?), dated as of September 28, 2021, is entered into by and among (i) LumiraDx Limited, a Cayman Island exempted company limited by shares with company number 314391 (the ?Company?); (ii) Continental Stock Transfer & Trust Company, a New York Limited Purpose Trust Company (the ?Outgoing Wa |
|
| September 29, 2021 |
As filed with the Securities and Exchange Commission on September 29, 2021. As filed with the Securities and Exchange Commission on September 29, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 LUMIRADX LIMITED (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| September 29, 2021 |
Exhibit 1.1 Memorandum and Articles of Association Of LUMIRADX LIMITED The Companies Act (as revised) of the Cayman Islands Company number: 314391 (Exempted company limited by shares) (Adopted by special resolution on 28 September 2021) Company number: 314391 (Exempted company limited by shares) (Adopted by special resolution on 28 September 2021) THE COMPANIES ACT (AS REVISED) MEMORANDUM OF ASSOC |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| September 29, 2021 |
Exhibit 4.5 LUMIRADX LIMITED 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the LumiraDx Limited 2021 Stock Option and Incentive Plan (this ?Plan?). The purpose of the Plan is to encourage and enable employees, Non-Employee Directors and Consultants of LumiraDx Limited, incorporated in the Cayman Islands (including any successor ent |
|
| September 29, 2021 |
Consent of KPMG LLP, independent registered accounting firm for LumiraDx Limited. Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the shell company report on Form 20-F of our report dated April 20, 2021, with respect to the consolidated financial statements of LumiraDx Limited, which report appears in Amendment No.2 to the registration statement (No. 333-257745) on Form F-4 of LumiraDx Limited and to the refe |
|
| September 29, 2021 |
Exhibit 4.6 LUMIRADX LIMITED 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries with an opportunity to acquire a proprietary interest in the Company through the purchase of shares of Stock. The Company intends for the Plan to qualify as an ?employee stock purchase plan? under Section 423 of the Code. The prov |
|
| September 29, 2021 |
Exhibit 4.4 Execution Version AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of the 28th day of September, 2021, is made and entered into by and among LumiraDx Limited, a limited company incorporated under the laws of the Cayman Islands (the ?Company?), CA Healthcare Acquisition Corp., a Delaware corporation ( |
|
| September 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 LUMIRADX LIMITED (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification |
|
| September 27, 2021 |
Exhibit 10.20 Aegle Care (Holdings) Limited EMI Option Scheme Adopted on 16 December 2014 Osborne Clarke 2 Temple Back East Temple Quay Bristol BS1 6EG Tel: +44 117 917 3000 Fax: +44 117 917 3005 Ref: SEH/1017243/23435823/SEH Contents 1. Definitions and interpretation 1 2. Purpose 3 3. Qualification requirements 4 4. Grant of Option 5 5. Rights to exercise Options 6 6. Procedures to exercise Optio |
|
| September 27, 2021 |
As filed with the Securities and Exchange Commission on September 27, 2021. As filed with the Securities and Exchange Commission on September 27, 2021. Registration No. 333-257745 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LUMIRADX LIMITED (Exact name of registrant as specified in its charter) Cayman Islands 2834 Not Applicable (State or other ju |
|
| September 10, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257745 SUPPLEMENT NO. 1, DATED SEPTEMBER 10, 2021 (to the Proxy Statement/Prospectus dated September 3, 2021) SUPPLEMENT TO PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS OF CA HEALTHCARE ACQUISITION CORP. PROSPECTUS FOR UP TO 14,780,000 LMDX COMMON SHARES 5,750,000 LMDX WARRANTS AND 5,750,000 LMDX COMMON SHARES UNDERLYING WARRANTS OF LUMI |
|
| September 3, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257745 PROXY STATEMENT/PROSPECTUS PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS OF CA HEALTHCARE ACQUISITION CORP. PROSPECTUS FOR UP TO 14,780,000 LMDX COMMON SHARES 5,750,000 LMDX WARRANTS AND 5,750,000 LMDX COMMON SHARES UNDERLYING WARRANTS OF LUMIRADX LIMITED The board of directors of CA Healthcare Acquisition Corp., |
|
| September 1, 2021 |
VIA EDGAR September 1, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 1, 2021 |
EXHIBIT 4.5 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.0000028 Certificate Shares Number * * 000000 ****************** * * * 000000 ***************** ZQ00000000 **** 000000 **************** LumiraDx Limited ***** 000000 *************** ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS ** Mr. Alexander David Sample **** Mr |
|
| September 1, 2021 |
Exhibit 4.6 FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF LumiraDx Limited (hereinafter called the ?Company?), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of the Memorandum and Articl |
|
| September 1, 2021 |
Form of Proxy Card for Special Meeting. Exhibit 99.1 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet?Q U I CK E A SY IMMEDIATE?24 Hours a Day, 7 Days a Week or by Mail CA HEALTHCARE ACQUISITION CORP. Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Easte |
|
| September 1, 2021 |
List of subsidiaries of LumiraDx Limited EX-21.1 6 d162386dex211.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES The following are the subsidiaries of LumiraDx Limited. Legal Name of Subsidiary Jurisdiction of Organization ACS Acquisition LLC United States Biomedical Service S.r.l. Italy Lumira SAS Colombia Lumira Healthcare Ltda Brazil LumiraDx (Pty) Limited South Africa LumiraDx A/S Denmark LumiraDx AB Sweden LumiraDx AS Norway LumiraDx Benelux |
|
| September 1, 2021 |
As filed with the Securities and Exchange Commission on September 1, 2021. As filed with the Securities and Exchange Commission on September 1, 2021. Registration No. 333-257745 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LUMIRADX LIMITED (Exact name of registrant as specified in its charter) Cayman Islands 2834 Not Applicable (State or other jurisdiction of in |
|
| August 27, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on August 27, 2021. |
|
| August 27, 2021 |
Exhibit 10.4 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this Agreement) is made as of [ ], by and between LumiraDx Limited, an exempted company incorporated in the Cayman Islands (the Company), and [ ] (the Indemnitee), [a director/an executive officer] of the Company. WHEREAS, the Indemnitee has agreed to serve as [a director/an executive officer] of the Company and in such capacit |
|
| August 27, 2021 |
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 August 27, 2021 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Celeste Murphy David Burton Jeanne Baker Re: LumiraDx Limited Amendment No. 1 to Registration Statement on Form F-4 Filed August 20, |
|
| August 27, 2021 |
Exhibit 4.10 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of [?], 2021, is made and entered into by and among LumiraDx Limited, a limited company incorporated under the laws of the Cayman Islands (the ?Company?), CA Healthcare Acquisition Corp., a Delaware corporation (?CAH?), CA Healthcare Sponsor LLC, a De |
|
| August 20, 2021 |
Exhibit 4.8 Execution Version CA HEALTHCARE ACQUISITION CORP. AMENDMENT TO THE AMENDED AND RESTATED SPONSOR AGREEMENT This AMENDMENT TO THE AMENDED AND RESTATED SPONSOR AGREEMENT (this ?Amendment?) is made as of August 19, 2021, by and among CA Healthcare Acquisition Corp., a Delaware corporation (?CAH?), CA Healthcare Sponsor LLC (the ?Sponsor?) and each of the undersigned individuals, each of wh |
|
| August 20, 2021 |
Filed by LumiraDx Limited Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: CA Healthcare Acquisition Corp. |
|
| August 20, 2021 |
Exhibit 4.21 Execution Version AMENDED AND RESTATED COMPANY HOLDERS SUPPORT AGREEMENT This Amended and Restated Company Holders Support Agreement (this ?Agreement?) is dated as of , 2021 by and between LumiraDx Limited, a Cayman Islands exempted company limited by shares with company number 314391 (the ?Company?) and each of the security holders of the Company whose names appear on the signature p |
|
| August 20, 2021 |
Form of LumiraDx Limited 2021 Stock Option and Incentive Plan Exhibit 10.3 [FINAL FORM] LUMIRADX LIMITED 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the LumiraDx Limited 2021 Stock Option and Incentive Plan (this ?Plan?). The purpose of the Plan is to encourage and enable employees, Non-Employee Directors and Consultants of LumiraDx Limited, incorporated in the Cayman Islands (including any |
|
| August 20, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on August 20, 2021. |
|
| August 20, 2021 |
Form of LumiraDx Limited 2021 Employee Stock Purchase Plan Exhibit 10.19 {FINAL FORM} LUMIRADX LIMITED 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries with an opportunity to acquire a proprietary interest in the Company through the purchase of shares of Stock. The Company intends for the Plan to qualify as an ?employee stock purchase plan? under Section 423 of the |
|
| August 20, 2021 |
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 August 20, 2021 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Celeste Murphy David Burton Jeanne Baker Re: LumiraDx Limited Registration Statement on Form F-4 Filed July 7, 2021 File No. 333-2577 |
|
| July 19, 2021 |
425 Transforming Community-Based Healthcare Analyst Day July 16, 2021 Confidential and Proprietary Copyright © 2021 LumiraDx Ltd. |
|
| July 7, 2021 |
Exhibit 10.14 EXECUTION VERSION LOAN AGREEMENT Dated as of March 23, 2021 among LUMIRADX INVESTMENT LIMITED (as Borrower, and a Credit Party), LUMIRADX GROUP LIMITED (as Parent, and a Credit Party), LUMIRADX LIMITED (as Issuer and a Credit Party), EACH OTHER GUARANTOR SIGNATORY HERETO AND OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral A |
|
| July 7, 2021 |
Exhibit 10.12 Books of Council and Session Extract Registered 28 Oct 2015 ASSIGNATION AND VARIATION ALERE TECHNOLOGIES LIMITED LUMIRA LIMITED Registers of Scotland AT EDINBURGH the Twenty Eighth day of October Two thousand and fifteen the Deed hereinafter reproduced was presented for registration in the Books of the Lords of Council and Session for preseJVation and execution and is registered in t |
|
| July 7, 2021 |
Specimen Unit Certificate of CAH Exhibit 4.1 NUMBER UNITS U- SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 12510W 206 CA HEALTHCARE ACQUISITION CORP. UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE-HALF OF ONE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (?Unit?) consists of one (1) share of Class A common stock, par v |
|
| July 7, 2021 |
Exhibit 10.13 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?), dated for reference purposes only July 29, 2016, is made by and between South Cedros Associates, LLC a California Limited Liability Company (?Lessor?) and Aegle Care, Inc. dba Lumira Dx (?Lessee?), (collectively th |
|
| July 7, 2021 |
EX-10.16 33 d162386dex1016.htm EX-10.16 Exhibit 10.16 Execution Version INTERCREDITOR AGREEMENT Dated 29 March 2021 Between THE SENIOR LENDERS THE 2019 JUNIOR LENDERS THE 2020 JUNIOR LENDERS, as Original Junior Lenders LUMIRADX LIMITED AND ITS SUBSIDIARIES NAMED IN SCHEDULE 1 HERETO, as Original Debtors BIOPHARMA CREDIT PLC as Security Agent And others Execution Version CONTENTS Clause Page 1. DEF |
|
| July 7, 2021 |
Certificate of Incorporation of CAH Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CA HEALTHCARE ACQUISITION CORP. January 26, 2021 CA Healthcare Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is ?CA Healthcare Acquisition Corp.?. The certificate of incorporation of the Corporation wa |
|
| July 7, 2021 |
EX-10.5 22 d162386dex105.htm EX-10.5 Exhibit 10.5 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTION VERSION October 17, 2019 LumiraDx Limited 3 More London Riverside London SEl 2AQ U |
|
| July 7, 2021 |
Exhibit 10.8 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. GRANT AGREEMENT [***] AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: LumiraDx UK Limited Tax Status: Not exempt fro |
|
| July 7, 2021 |
Exhibit 4.19 EXECUTION VERSION Warrant Instrument in respect of Warrants to subscribe for Common Shares issued by LumiraDx Limited to BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP [?] 2021 100 Bishopsgate London EC2N 4AG Tel: +44 20 7972 9600 Fax: +44 20 7972 9602 TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 3 2. WARRANT ISSUE AND SUBSCRIPTION RIGHTS 8 3. EXER |
|
| July 7, 2021 |
Exhibit 4.14 Convertible Loan Instrument constituting up to US$150,000,000 Convertible Loan Notes (as defined herein) Between LumiraDx Limited and Wilmington Trust SP Services (London) Limited 1 JULY 2020 i TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 1 2. AMOUNT OF THE CONVERTIBLE LOAN NOTES 4 3. STATUS OF THE CONVERTIBLE LOAN NOTES 4 4. CONDITIONS OF ISSUE 5 5. CERTIFICATES FOR THE C |
|
| July 7, 2021 |
Exhibit 4.4 Final Form AMENDED AND RESTATED WARRANT AGREEMENT THIS AMENDED AND RESTATED WARRANT AGREEMENT (this ?Agreement?), dated as of [], 2021, is entered into by and among LumiraDx Limited, a Cayman Island exempted company limited by shares with company number 314391 (the ?Company?), Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the ?Warrant Agent?, als |
|
| July 7, 2021 |
Exhibit 4.11 Warrant Instrument in respect of Warrants to subscribe for A Ordinary Shares ([?] Lender) LumiraDx Limited 20 September 2019 41 Lothbury London EC2R 7HF Tel: +44 20 7972 9600 Fax: +44 20 7972 9602 TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 3 2. WARRANT ISSUE AND SUBSCRIPTION RIGHTS 8 3. REPRESENTATIONS BY THE [?] LENDER; REPRESENTATIONS BY THE COMPANY; LEGEND 11 4. EXERC |
|
| July 7, 2021 |
Exhibit 3.2 Memorandum and Articles of Association Of LUMIRADX LIMITED The Companies Act (as revised) of the Cayman Islands Company number: 314391 (Exempted company limited by shares) (Adopted by special resolution on [?] 2021) Company number: 314391 (Exempted company limited by shares) (Adopted by special resolution on [?] 2021) THE COMPANIES ACT (AS REVISED) MEMORANDUM OF ASSOCIATION OF LUMIRADX |
|
| July 7, 2021 |
EX-10.2 21 d162386dex102.htm EX-10.2 Exhibit 10.2 LumiraDx Limited Unapproved Option Scheme with US Appendix Adopted by a resolution of the Board on 19 September 2016 and amended by the Board on 26 September 2016, 28 October 2016 and 17 January 2018 Contents 1. Definitions and interpretation 1 2. Grant of Option 3 3. Rights to exercise Options 4 4. Procedures to exercise Options 7 5. Release |
|
| July 7, 2021 |
EX-10.6 23 d162386dex106.htm EX-10.6 Exhibit 10.6 EXECUTION VERSION Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. LUMIRADX LIMITED NOTE PURCHASE AGREEMENT OCTOBER 17, 2019 CONTENTS 1. Defi |
|
| July 7, 2021 |
Exhibit 10.18 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), is made as of the 30th day of November, 2020, by and among LumiraDx Limited, an exempted company with limited liability incorporated in the Cayman Islands (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. Capitaliz |
|
| July 7, 2021 |
Exhibit 10.9 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Exclusivity Agreement This Exclusivity Agreement (including all exhibits attached hereto is referred to herein, collectively, as |
|
| July 7, 2021 |
Exhibit 4.10 Confidential DATED 3 OCTOBER 2016 LumiraDx Limited WARRANT INSTRUMENT IN RESPECT OF WARRANTS TO SUBSCRIBE FOR A ORDINARY SHARES IN LUMIRADX LIMITED NORTON ROSE FULBRIGHT Contents Clause Page 1 Definitions and interpretation 2 2 Subscription Rights 6 3 Exercising Subscription Rights 7 4 Issue of Shares upon Exercise of Subscription Rights 8 5 Restrictions and Obligations of the Company |
|
| July 7, 2021 |
Exhibit 4.7 Execution Version CA Healthcare Acquisition Corp. 99 Summer Street Suite 200 Boston, MA 02110 April 6, 2021 Re: Amended and Restated Sponsor Agreement Ladies and Gentlemen: This letter (this ?Sponsor Agreement?) is being delivered to you in connection with that certain Agreement and Plan of Merger, dated as of the date hereof (the ?Merger Agreement?), by and among LumiraDx Limited, a C |
|
| July 7, 2021 |
Exhibit 4.12 Convertible Loan Instrument constituting up to US$150,000,000 Convertible Loan Notes (as defined herein) Between LumiraDx Limited and Wilmington Trust SP Services (London) 15 October 2019 i TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 1 2. AMOUNT OF THE CONVERTIBLE LOAN NOTES 3 3. STATUS OF THE CONVERTIBLE LOAN NOTES 4 4. CONDITIONS OF ISSUE 4 5. CERTIFICATES FOR THE CONVE |
|
| July 7, 2021 |
Memorandum and Articles of Association of LumiraDx Limited, as currently in effect Exhibit 3.1 The Companies Law (as revised) of the Cayman Islands Memorandum and Articles of Association of LUMIRADX LIMITED Company number: 314391 (Exempted company limited by shares) (Adopted by Special Resolution on 4 November 2020) THE COMPANIES LAW (AS REVISED) MEMORANDUM OF ASSOCIATION OF LUMIRADX LIMITED 1 The name of the Company is LumiraDx Limited. 2 The registered office will be situated |
|
| July 7, 2021 |
Purchase Agreement, dated August 14, 2020, by and between LumiraDx Inc. and CVS Pharmacy, Inc. Exhibit 10.10 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Purchase Agreement Between CVS Pharmacy, Inc. And LumiraDx, Inc 1. Overview and Background of Agreement This Purchase Agreement |
|
| July 7, 2021 |
Exhibit 10.1 LumiraDx Limited Consultants? and Non-Employees? Option Scheme Adopted by resolution of the Board on 19 September 2016 and amended by the Board on 26 September 2016, 28 October 2016 and 17 January 2018 Contents 1. Definitions and interpretation 3 2. Grant of Option 5 3. Rights to exercise Options 6 4. Procedures to exercise Options 9 5. Release of Options 10 6. Adjustment of Options 1 |
|
| July 7, 2021 |
Exhibit 10.7 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. GRANT AGREEMENT [***] AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: LumiraDx UK Limited Tax Status: Not exempt fro |
|
| July 7, 2021 |
Specimen Class A Common Stock Certificate of CAH Exhibit 4.2 NUMBER NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 12510W 107 CA HEALTHCARE ACQUISITION CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CLASS A COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE CLASS A COMMON STOCK OF CA HEALTHCARE ACQUISITION CORP. (THE ?COMPANY?) transferable on the |
|
| July 7, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on July 7, 2021. |
|
| July 7, 2021 |
Exhibit 10.11 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. FLEXTRONICS CONFIDENTIAL Flextronics Manufacturing Services Agreement This Flextronics Manufacturing Services Agreement (?Agreem |
|
| July 7, 2021 |
Exhibit 10.17 REGISTRATION RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 8 2.6 Expenses of Registration 8 2.7 Delay of Registration 9 2.8 Indemnification 9 2.9 Reports Under Exchange Act 11 2.10 Limitations on Subsequent R |
|
| July 7, 2021 |
July 7, 2021 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Celeste Murphy David Burton Jeanne Baker Re: LumiraDx Limited Amendment No. 1 to Draft Registration Statement on Form F-4 Submitted June 16, 2021 CIK 0001685428 Ladies and Gentlemen: On behalf of our client, LumiraDx Limited |
|
| July 7, 2021 |
Exhibit 10.15 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. GRANT AGREEMENT [***] AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: LumiraDx UK Limited Tax Status: Not exempt fr |
|
| July 7, 2021 |
List of subsidiaries of LumiraDx Limited Exhibit 21.1 SUBSIDIARIES The following are the subsidiaries of LumiraDx Limited. Legal Name of Subsidiary Jurisdiction of Organization ACS Acquisition LLC United States Biomedical Service S.r.l. Italy Lumira SAS Colombia LumiraDx (Pty) Limited South Africa LumiraDx A/S Denmark LumiraDx AB Sweden LumiraDx AS Norway LumiraDx B.V. Netherlands LumiraDx Brazil Holdings Limited United Kingdom LumiraDx |
|
| July 7, 2021 |
Exhibit 4.17 EXECUTION VERSION Warrant Instrument in respect of Warrants to subscribe for Common Shares issued by LumiraDx Limited to Jefferies Finance LLC 6 November 2020 100 Bishopsgate London EC2N 4AG Tel: +44 20 7972 9600 Fax: +44 20 7972 9602 TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 3 2. WARRANT ISSUE AND SUBSCRIPTION RIGHTS 7 3. EXERCISING SUBSCRIPTION RIGHTS 8 4. ISSUE OF SH |
|
| July 7, 2021 |
Exhibit 4.18 EXECUTION VERSION Warrant Instrument in respect of Warrants to subscribe for Common Shares issued by LumiraDx Limited to Silicon Valley Bank 20 January 2021 100 Bishopsgate London EC2N 4AG Tel: +44 20 7972 9600 Fax: +44 20 7972 9602 TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 3 2. WARRANT ISSUE AND SUBSCRIPTION RIGHTS 7 3. EXERCISING SUBSCRIPTION RIGHTS 8 4. ISSUE OF SHAR |
|
| July 7, 2021 |
Specimen Warrant Certificate of CAH Exhibit 4.3 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW CA HEALTHCARE ACQUISITION CORP. Incorporated Under the Laws of the State of Delaware CUSIP 12510W 115 Warrant Certificate This Warrant Certificate certifies that , or registered assigns, is |
|
| July 7, 2021 |
Exhibit 4.16 Warrant Instrument in respect of Warrants to subscribe for Common Shares in LumiraDx Limited LumiraDx Limited 1 July 2020 41 Lothbury London EC2R 7HF Tel: +44 20 7972 9600 Fax: +44 20 7972 9602 IMPORTANT NOTICE THE CONTENT OF THIS WARRANT INSTRUMENT HAS NOT BEEN APPROVED BY AN AUTHORISED PERSON WITHIN THE MEANING OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (?FSMA?). RELIANCE ON THI |
|
| July 7, 2021 |
Execution Version Exhibit 4.8 COMPANY HOLDERS SUPPORT AGREEMENT This Company Holders Support Agreement (this ?Agreement?) is dated as of April 6, 2021 by and between LumiraDx Limited, a Cayman Islands exempted company limited by shares with company number 314391 (the ?Company?) and each of the security holders of the Company whose names appear on the signature pages of this Agreement (each, a ?Hol |
|
| June 16, 2021 |
DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 15, 2021 as Amendment No. 1 to the initial confidential submission. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIE |
|
| June 15, 2021 |
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 June 15, 2021 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Celeste Murphy David Burton Jeanne Baker Re: LumiraDx Limited Draft Registration Statement on Form F-4 Submitted April 20, 2021 CIK 000 |
|
| April 20, 2021 |
EX-10.5 21 filename21.htm Exhibit 10.5 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTION VERSION October 17, 2019 LumiraDx Limited 3 More London Riverside London SEl 2AQ United Kingd |
|
| April 20, 2021 |
LUMIRADX LIMITED NOTE PURCHASE AGREEMENT OCTOBER 17, 2019 Exhibit 10.6 EXECUTION VERSION Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. LUMIRADX LIMITED NOTE PURCHASE AGREEMENT OCTOBER 17, 2019 CONTENTS 1. Definitions 2 2. Amount and Terms of the |
|
| April 20, 2021 |
Exhibit 3.2 Memorandum and Articles of Association Of LUMIRADX LIMITED The Companies Act (as revised) of the Cayman Islands Company number: 314391 (Exempted company limited by shares) (Adopted by special resolution on [?] 2021) Company number: 314391 (Exempted company limited by shares) (Adopted by special resolution on [?] 2021) THE COMPANIES ACT (AS REVISED) MEMORANDUM OF ASSOCIATION OF LUMIRADX |
